DK1097922T3 - 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel - Google Patents

5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel

Info

Publication number
DK1097922T3
DK1097922T3 DK99929831T DK99929831T DK1097922T3 DK 1097922 T3 DK1097922 T3 DK 1097922T3 DK 99929831 T DK99929831 T DK 99929831T DK 99929831 T DK99929831 T DK 99929831T DK 1097922 T3 DK1097922 T3 DK 1097922T3
Authority
DK
Denmark
Prior art keywords
thia
prostaglandin
omega
substituted phenyl
disease
Prior art date
Application number
DK99929831T
Other languages
English (en)
Inventor
Toru Maruyama
Shuichi Ohuchida
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of DK1097922T3 publication Critical patent/DK1097922T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK99929831T 1998-07-15 1999-07-14 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel DK1097922T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20075298 1998-07-15
PCT/JP1999/003798 WO2000003980A1 (fr) 1998-07-15 1999-07-14 DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF

Publications (1)

Publication Number Publication Date
DK1097922T3 true DK1097922T3 (da) 2005-05-30

Family

ID=16429595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99929831T DK1097922T3 (da) 1998-07-15 1999-07-14 5-Thia-omega-substituerede phenyl-prostaglandin E derivater, fremgangsmåde til fremstilling deraf samt lægemidler indeholdende forbindelsen som aktiv bestanddel

Country Status (21)

Country Link
US (1) US6462081B1 (da)
EP (1) EP1097922B1 (da)
JP (1) JP3174563B2 (da)
KR (1) KR100598660B1 (da)
CN (1) CN1173945C (da)
AT (1) ATE291013T1 (da)
AU (1) AU763668B2 (da)
BR (1) BR9912813B1 (da)
CA (1) CA2336952C (da)
DE (1) DE69924258T2 (da)
DK (1) DK1097922T3 (da)
ES (1) ES2239448T3 (da)
HU (1) HUP0204170A3 (da)
NO (1) NO327781B1 (da)
NZ (1) NZ509293A (da)
PT (1) PT1097922E (da)
RU (1) RU2220135C2 (da)
TR (1) TR200100623T2 (da)
TW (1) TWI249520B (da)
WO (1) WO2000003980A1 (da)
ZA (1) ZA200100295B (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
EP1226825A4 (en) * 1999-10-07 2004-08-11 Ono Pharmaceutical Co MEDICINE FOR ERECTILE DYSFUNCTION
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
KR20020067594A (ko) * 2000-01-05 2002-08-22 오노 야꾸힝 고교 가부시키가이샤 5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US6586462B2 (en) * 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
PL215425B1 (pl) * 2001-07-16 2013-12-31 Ono Pharmaceutical Co Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
JP2003078830A (ja) * 2001-09-03 2003-03-14 Sony Corp デジタル放送受信装置および通信情報伝送方法
WO2003030911A1 (en) * 2001-10-08 2003-04-17 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
ATE371454T1 (de) * 2001-10-31 2007-09-15 Medical Res Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
EP1490055A1 (en) * 2002-03-18 2004-12-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
GB0208785D0 (en) * 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
EP1513589B1 (en) * 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
ATE401895T1 (de) * 2002-08-09 2008-08-15 Taisho Pharmaceutical Co Ltd Antipruritisches mittel
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
WO2004043471A1 (ja) * 2002-11-13 2004-05-27 Taisho Pharmaceutical Co., Ltd. 鎮痒剤
BRPI0407258A (pt) * 2003-02-07 2006-01-31 Ono Pharmaceutical Co Compostos de ácido carboxìlico
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
JP4662926B2 (ja) 2003-03-03 2011-03-30 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγ−ラクタム誘導体
EP1654219A2 (en) 2003-07-18 2006-05-10 Applied Research Systems ARS Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
US7858610B2 (en) * 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
EP1782829A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
EP1878429B1 (en) 2005-04-28 2011-08-03 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7511168B2 (en) 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US8410171B2 (en) 2006-10-26 2013-04-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
CN101686985A (zh) 2007-05-08 2010-03-31 国立大学法人浜松医科大学 含有ep4激动剂的细胞毒性t细胞的活化剂
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010096123A2 (en) 2008-10-29 2010-08-26 Aerie Pharmaceuticals, Inc. Amino acid salts of prostaglandins
EP2383263B1 (en) 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
WO2010126626A2 (en) 2009-05-01 2010-11-04 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CN103068382A (zh) * 2010-07-30 2013-04-24 阿勒根公司 用于皮肤修复的化合物和方法
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
EP2875022B1 (en) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
JPH072711B2 (ja) 1986-09-24 1995-01-18 帝人株式会社 プロスタグランジンｅ▲下１▼誘導体の製造法
EP0386901A1 (en) * 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. Novel 5-hetero-6-oxo-PGE derivatives
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JP3579448B2 (ja) 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用

Also Published As

Publication number Publication date
TWI249520B (en) 2006-02-21
EP1097922A1 (en) 2001-05-09
NO20010213L (no) 2001-03-15
BR9912813A (pt) 2001-05-02
EP1097922A4 (en) 2003-02-12
DE69924258T2 (de) 2006-01-26
NO20010213D0 (no) 2001-01-12
EP1097922B1 (en) 2005-03-16
US6462081B1 (en) 2002-10-08
DE69924258D1 (de) 2005-04-21
ZA200100295B (en) 2002-07-10
PT1097922E (pt) 2005-06-30
CA2336952C (en) 2009-09-15
TR200100623T2 (tr) 2001-06-21
CN1312796A (zh) 2001-09-12
KR20010053386A (ko) 2001-06-25
ES2239448T3 (es) 2005-09-16
HUP0204170A2 (hu) 2003-04-28
KR100598660B1 (ko) 2006-07-13
AU4651899A (en) 2000-02-07
HUP0204170A3 (en) 2005-03-29
JP3174563B2 (ja) 2001-06-11
CN1173945C (zh) 2004-11-03
CA2336952A1 (en) 2000-01-27
BR9912813B1 (pt) 2010-11-30
AU763668B2 (en) 2003-07-31
RU2220135C2 (ru) 2003-12-27
WO2000003980A1 (fr) 2000-01-27
NO327781B1 (no) 2009-09-21
ATE291013T1 (de) 2005-04-15
NZ509293A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
NO20010213L (no) 5-tia-<omega>-substituerte fenyl-prostaglandin-E-derivater, fremgangsmÕte ved fremstilling av slike samt medikamenter omfattende slike som aktiv bestanddel
ES2196527T3 (es) Derivados de 11,15-o-dialquilprostaglandina e, su procedimiento de produccion y medicamentos que incluyen estos como principio activo.
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
JP2012513412A5 (da)
DK1080726T3 (da) Midler til lindring af bivirkninger
DE68906609D1 (de) Dopamin-vorlaeufer.
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
DK0615754T3 (da) Faste flupertinholdige orale administrationsformer med kontrolleret frigivelse af den aktive forbindelse
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
EP1258473A4 (en) BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
IT1271007B (it) Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
IT1256320B (it) Derivati eterociclici
WO2004022699A3 (en) Liquid stable composition of oxazaphosphorine with mesna
Kerr et al. Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analog 2', 3'-dideoxycytidine and its 3'-fluoro derivative
NO20010454D0 (no) Anvendelse av derivater av camptotécin med en redusert gastrointestinal toksisitet
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
KR900012925A (ko) 인돌 유도체
ZA801505B (en) Tetracyclic indole derivatives
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
NO20013408L (no) Anvendelse av 2-substituerte 1,2-benzisotiazol-derivater og 3- substituerte tetrahydropyridopyrimidinon-derivater for profylakseog terapi av cerebral ischemi
ATE307131T1 (de) Phenanthrolin-7-onderivate und ihre therapeutische verwendung
DK0998464T3 (da) Polyhydroxyalkylpyrazinderivater, deres fremstilling samt medikamenter indeholdende disse forbindelser
RU2002106908A (ru) Противотуберкулезный препарат